A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).

Trial Details

NCT ID

NCT07559929

Phase

PHASE1 / PHASE2

Sponsor

Hangzhou DAC Biotechnology Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

DXC006
Toripalimab
Carboplatin
Cisplatin

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Voluntarily signed informed consent and willingness to comply with the protocol requirements.
Male or female.
Age ≥18 years and ≤75 years.
Life expectancy ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →